NASDAQ$MRUS

Merus Nv · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Merus reported Q1 2025 revenue of $26.5M, a net loss of $94.6M, diluted EPS of $-1.02.

For Q1 2025, Merus reported Revenue was $26.5M, net loss was $94.6M, diluted EPS was $-1.02. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Revenue $26.5M for Q1 2025.
  • Net loss $94.6M.
  • Diluted EPS $-1.02.

Headline financials

Total Revenue

$26.5M

Previous: $7.89M+235.8%
EPS (adj)

-$1.02

Previous: -$0.59-72.9%
R&D Expense

$80.1M

No prior period
G&A Expense

$22.1M

No prior period
Total Operating Expenses

$102M

No prior period
Interest Income

$7.2M

No prior period
Foreign Exchange Loss

-$24.3M

No prior period
Other Income

-$18.9M

No prior period
Income Tax Expense

$1.86M

No prior period
Currency Translation Adjustment

$23.1M

No prior period
Comprehensive Loss

-$73.4M

No prior period
Weighted Avg. Shares Outstanding

69.0M

No prior period
Marketable Securities

$261M

No prior period
Accounts Receivable

$14.2M

No prior period
Prepaid & Other Current Assets

$49.7M

No prior period
Total Current Assets

$522M

No prior period
Property & Equipment, Net

$10.9M

No prior period
Operating Lease ROU Assets

$9.2M

No prior period
Intangible Assets, Net

$1.7M

No prior period
Deferred Tax Assets

$364K

No prior period
Other Assets

$3.11M

No prior period
Accounts Payable

$8.98M

No prior period
Accrued Expenses & Liabilities

$42.8M

No prior period
Income Taxes Payable

$8.02M

No prior period
Current Lease Obligation

$1.77M

No prior period
Current Deferred Revenue

$27.6M

No prior period
Total Current Liabilities

$89.1M

No prior period
Lease Obligation

$8.08M

No prior period
Deferred Revenue (Non-current)

$37.6M

No prior period
Total Liabilities

$135M

No prior period
Common Shares Outstanding

69.2M

No prior period
Additional Paid-In Capital

$1.69B

No prior period
Accumulated Deficit

-$1.06B

No prior period
Accum. Other Comprehensive Income

-$32.4M

No prior period
Total Shareholders’ Equity

$596M

No prior period
Net Income

-$94.6M

Previous: -$34.5M-174.6%
Operating Income

-$75.7M

Previous: -$46.8M-61.8%

Revenue & EPS history

Merus · Revenue · Quarterly

$26.5M

Q1 2025+235.8%vs Q1 2024
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Forward guidance

Outlook emphasizes clinical milestones, liquidity runway, and cost discipline.

Tailwinds

  • Pipeline readouts and partnership economics.
  • Cash balance supports near-term development plans.

Headwinds

  • Operating losses and trial risk until commercialization.
  • Financing markets and competition affect funding costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 8 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+0.5%

Avg return

Earnings day

-1.1%

Avg return

5 days after

-0.7%

Avg return

30 days after

49%

19 / 39 earnings

Positive

+19.7%

Q3 2023

Best reaction

-16.2%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025-0.2%+0.2%+1.0%
Q2 2025-2.8%-4.2%+0.1%
Q1 2025-0.3%+0.4%+28.4%
Q4 2024+1.5%+3.6%-18.8%
Q3 2024-1.9%+0.8%-12.4%
Q2 2024-1.8%-5.8%-4.3%
Q1 2024-7.4%-5.8%+8.7%
Q4 2023-0.9%+2.3%-8.1%
Q3 2023+19.7%
Q2 2023-11.7%
Q1 2023+9.9%
Q4 2022+4.0%
Q3 2022-16.2%
Q2 2022-8.4%
Q1 2022+0.8%
Q4 2021+6.4%
Q3 2021+8.1%
Q2 2021+3.0%
Q1 2021-3.8%
Q4 2020+3.2%
Q3 2020-3.2%
Q2 2020-1.5%
Q1 2020+3.5%
Q4 2019+11.9%
Q3 2019-0.8%
Q2 2019+7.7%
Q1 2019+3.0%
Q4 2018+3.8%
Q3 2018+2.5%
Q2 2018-2.8%
Q1 2018-1.1%
Q4 2017+2.6%
Q3 2017-7.1%
Q2 2017+5.0%
Q1 2017+0.1%
Q4 2016-3.5%
Q3 2016+4.2%
Q2 2016-1.5%
Q1 2016-3.4%
Q4 2014
Q2 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro